Bifidobacterium breve and memory

What 3 graded rows on bifidobacterium breve agree on for memory, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Bifidobacterium breve page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Bifidobacterium breve page, with its PubMed record.

Supplement

Bifidobacterium breve Choose another

3 rows · 311 people

Split. 1 row found an improvement, 1 found no difference and 1 had mixed results.

No difference or mixed

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside. Outlined: mixed results.

From the rows

How longWhen published

The best-graded row, grade C, is a randomized trial of 117 people (2019) and found no difference.

The row that found an improvement ran longer (4 months) than the row that found no difference (3 months).

The row that found an improvement is newer (2020) than the row that found no difference (2019).

1 row with mixed results is left out of this comparison.

1 improved · 1 no difference · 1 mixed

Grade CMemory and cognition in suspected mild cognitive impairment (strain A1) · Improved
RCT · n 79 · 2020 · Physically healthy older adults with suspected mild cognitive impairment (Japan)
2 × 10¹⁰ CFU/day · 16 weeks
RBANS total score improved versus placebo (mean difference 11.3 points), driven by immediate memory, visuospatial and delayed memory; no adverse events.
Row on the Bifidobacterium breve page · PubMed 32623402 (opens PubMed)
Grade CCognition in older adults with memory complaints (strain A1) · No difference
RCT · n 117 · 2019 · Older adults with memory complaints (Japan)
Daily capsules (CFU not stated in the abstract) · 12 weeks
Scores rose in both groups with no difference from placebo overall; in people with low baseline scores, immediate memory and MMSE improved more on A1. No adverse effects.
Row on the Bifidobacterium breve page · PubMed 31090457 (opens PubMed)
Grade CCognition and brain atrophy in suspected mild cognitive impairment (strain A1) · Mixed
RCT · n 115 · 2022 · Adults aged 65–88 with suspected mild cognitive impairment
2 × 10¹⁰ CFU once daily · 24 weeks
The ADAS-Jcog "orientation" subscale improved versus placebo at 24 weeks; two MMSE subscales improved only in people with a baseline MMSE below 25. Brain atrophy scores (VSRAD) worsened on placebo, and the probiotic tended to slow this, mainly in people with more atrophy at the start.
Row on the Bifidobacterium breve page · PubMed 35570493 (opens PubMed)